Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
LABT
Lakewood-Amedex Biotherapeutics, Inc.
CAPPED RATING
Lakewood-Amedex Biotherapeutics, Inc. (LABT) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (F).
Quantitative Factor Evaluation • Updated
Overall Rating
1.8
/ 5.0
D+
Value
B+
Factor Score
3.7
/ 5.0
Growth
D+
Factor Score
1.8
/ 5.0
Profitability
F
Factor Score
0.6
/ 5.0
Momentum
F
Factor Score
0.3
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
N/A
EV / EBITDA
0.5
Rev Growth YoY
N/A
Gross Margin
0.0%
Price Return 3M
-84.1%
Price Return 12M
-99.6%
Catalyst Signal
0.00
Market Cap
$851.2K
TTM Revenue
N/A
Price / Sales
N/A
ROE
-402.8%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | B+ (3.7) | D+ (1.8) | F (0.6) | F (0.3) | C+ (2.6) | D+ (1.8) |
| 2026-11-06 | A- (3.9) | D+ (1.8) | F (0.6) | F (0.4) | C+ (2.7) | C- (1.9) |
| 2026-10-30 | B+ (3.7) | D+ (1.8) | D- (0.7) | F (0.3) | C+ (2.7) | D+ (1.8) |
| 2026-10-23 | B+ (3.7) | C- (1.9) | F (0.7) | F (0.3) | C+ (2.6) | D+ (1.8) |
| 2026-10-16 | B+ (3.7) | D+ (1.8) | F (0.7) | F (0.5) | C+ (2.6) | C- (1.9) |
Page
1
of
4